Cantor Fitzgerald Analysts Give Heron Therapeutics, Inc. (HRTX) a $31.00 Price Target
A number of other research firms have also commented on HRTX. Jefferies Group LLC reaffirmed a buy rating on shares of Heron Therapeutics in a research report on Wednesday, August 16th. Northland Securities initiated coverage on Heron Therapeutics in a research report on Wednesday, September 27th. They set an outperform rating and a $40.00 price target for the company. Noble Financial reaffirmed a buy rating and set a $24.00 price target on shares of Heron Therapeutics in a research report on Friday, October 6th. Zacks Investment Research raised Heron Therapeutics from a hold rating to a buy rating and set a $14.00 price target for the company in a research report on Wednesday, July 12th. Finally, BidaskClub lowered Heron Therapeutics from a hold rating to a sell rating in a research report on Friday, August 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. Heron Therapeutics presently has a consensus rating of Buy and an average target price of $28.50.
Shares of Heron Therapeutics (NASDAQ HRTX) traded up 1.821% during midday trading on Thursday, reaching $15.375. The company’s stock had a trading volume of 475,300 shares. The company’s 50-day moving average price is $15.64 and its 200 day moving average price is $15.24. The company’s market capitalization is $832.37 million. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $20.85.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.10. The business had revenue of $8.51 million for the quarter, compared to the consensus estimate of $4.53 million. On average, equities research analysts forecast that Heron Therapeutics will post ($3.50) earnings per share for the current year.
Several large investors have recently made changes to their positions in HRTX. Janus Henderson Group PLC bought a new position in shares of Heron Therapeutics in the 2nd quarter worth approximately $78,134,000. Vanguard Group Inc. raised its position in shares of Heron Therapeutics by 40.2% in the 1st quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock worth $28,127,000 after acquiring an additional 537,563 shares in the last quarter. State Street Corp raised its position in shares of Heron Therapeutics by 30.7% in the 1st quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock worth $26,822,000 after acquiring an additional 420,113 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Heron Therapeutics in the 1st quarter worth approximately $2,002,000. Finally, Credit Suisse AG raised its position in shares of Heron Therapeutics by 329.8% in the 1st quarter. Credit Suisse AG now owns 144,061 shares of the biotechnology company’s stock worth $2,161,000 after acquiring an additional 110,539 shares in the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.